All Press Releases for December 18, 2023

Satish C. Tripathi, PhD, MPH, has been Inducted into the Prestigious Marquis Who's Who Biographical Registry

Satish C. Tripathi is recognized for his expert leadership of Biomedical Consulting International, Inc.



Since 2020, he has focused his efforts on providing consulting services from a developmental perspective and on the global registration for pharmaceuticals, biologics and medical devices.

    HIGHLAND PARK, IL, December 18, 2023 /24-7PressRelease/ -- Satish C. Tripathi, PhD, MPH, has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

With more than four decades of excellence in biotechnology and pharmaceuticals, Dr. Tripathi has earned distinction as the president of Biomedical Consulting International, Inc. Since 2020, he has focused his efforts on providing consulting services from a developmental perspective and on the global registration for pharmaceuticals, biologics and medical devices. Additionally, he has served as the founder of Ek Kadam Aur in the US since 2015 and Ek Kadam Aur Foundation for Education and Health in India since 2017. He is also a valued member of the Association of Government Toxicologists, the FDA (Food and Drug Administration) Alumni Association and the American Society of Gene and Cell Therapy, among other professional organizations.

Before establishing his company, Dr. Tripathi began his career as a research scientist in anatomy and cellular biology from the Medical College of Wisconsin in 1985 and became a visiting scientist in molecular biology from the Emory University School of Medicine in 1987. He subsequently served as a postdoctoral scientist and research fellow in toxicology with the Massachusetts Institute of Technology in 1989 and became a pharmacology-toxicology reviewer for the Food and Drug Administration in 1994. Following this time, he was a senior manager for United States regulatory affairs for Bracco Diagnostics in 1998 and the director of global regulatory affairs for the biosciences division of Baxter Healthcare Corporation in 2000.

Dr. Tripathi continued his career as the director for worldwide regulatory strategy for Pfizer in 2001 and became the vice president of regulatory affairs and quality assurance for Syneos Health in 2007. He then took a role as the president of Biomedical Consulting International, Inc. in 2008 and became the senior director of global regulatory affairs for Johnson & Johnson in 2011. He joined Genentech as the vice president of global regulatory affairs and clinical quality assurance in 2013, taking a position as the senior vice president and head of department for global regulatory affairs for Iveric Bio (Astellas) in 2015. In 2016, he served as the vice president of global regulatory affairs, clinical quality assurance and pharmacology for Novartis Gene Therapies.

To prepare for his professional journey, Dr. Tripathi earned a Bachelor of Science in biology in 1975 and a Master of Science in botany in 1977, both from Jiwaji University in India. Following these achievements, he attained a Master of Philosophy in genetics from Barkatullah University in Bhopal in 1978 and a Doctor of Philosophy in cell biology from the University of Glasgow in the United Kingdom in 1984. He subsequently gained a Master of Public Health from Columbia University in 2012 and was admitted as an advanced leadership initiative fellow by Harvard University in 2022. Well-qualified in his field, he secured a regulatory affairs certification from the Regulatory Affairs Professionals Society.

Looking to the future, Dr. Tripathi intends to have another drug approved worldwide and then shift his focus on helping children who are completely blind and who do not go to school due to poverty. He is particularly proud to have contributed to the market approval for 15 medications and to have helped develop Zolgensma, a gene therapy, which is used to treat children younger than two years old with spinal muscular atrophy.

About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Marquis celebrates its 125th anniversary in 2023, and Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® publications may be visited at the official Marquis Who's Who® website at www.marquiswhoswho.com.

# # #

Contact Information

-- --
Marquis Who's Who Ventures LLC
Uniondale, NY
USA
Voice: 844-394-6946
E-Mail: Email Us Here
Website: Visit Our Website
Follow Us: